|  | value |
| --- | --- |
| Donor type | |
| HLA identical sibling | 1010 (61.55%) |
| Mismatched unrelated donor and cord blood | 175 (10.66%) |
| Matched unrelated donor | 167 (10.18%) |
| HLA mismatch relative | 289 (17.61%) |
| Graft type | |
| Peripheral blood | 333 (20.29%) |
| Bone marrow | 1137 (69.29%) |
| Umbilical cord blood | 171 (10.42%) |
| Conditioning intensity | |
| Reduced-intensity conditioning | 378 (23.03%) |
| Myeloablative | 833 (50.76%) |
| NA | 64 (3.9%) |
| Non-myeloablative | 366 (22.3%) |
| Conditioning regimen | |
| Flu/Bu | 264 (16.09%) |
| Bu/Cy | 546 (33.27%) |
| TBI/Cy | 23 (1.4%) |
| TBI/Flu | 13 (0.79%) |
| TBI/Cy/Flu | 110 (6.7%) |
| Flu/Mel | 274 (16.7%) |
| Bu/Mel | 1 (0.06%) |
| NA | 31 (1.89%) |
| Cy/Flu | 9 (0.55%) |
| Flu/Mel/TT | 114 (6.95%) |
| Flu/Bu/TT | 21 (1.28%) |
| TBI alone (300/400cGy) | 121 (7.37%) |
| Treosulfan | 8 (0.49%) |
| TBI/Mel | 6 (0.37%) |
| TBI/Cy/Flu/TT | 98 (5.97%) |
| Cy alone | 2 (0.12%) |
| ATG/Alemtuzumab given as conditioning regimen/GVHD prophylaxis | |
| Alemtuzumab | 700 (42.66%) |
| None | 134 (8.17%) |
| ATG | 780 (47.53%) |
| NA | 27 (1.65%) |
| GVHD prophylaxis | |
| CNI alone | 110 (6.7%) |
| CNI + MTX | 710 (43.27%) |
| MTX alone | 12 (0.73%) |
| CNI + MMF | 308 (18.77%) |
| Ex-vivo T-cell depletion | 25 (1.52%) |
| CD 34 selection | 61 (3.72%) |
| NA | 34 (2.07%) |
| Post-CY + MMF + CNI | 59 (3.6%) |
| MMF + MTX | 1 (0.06%) |
| MMF alone | 5 (0.3%) |
| Post-CY + siro +/- MMF | 189 (11.52%) |
| Siro alone | 115 (7.01%) |
| CNI + siro | 6 (0.37%) |
| MMF + siro | 4 (0.24%) |
| MTX + siro | 2 (0.12%) |
| Donor-recipient HLA matching | |
| 8/8 | 1177 (71.72%) |
| <=6/8 | 383 (23.34%) |
| 7/8 | 80 (4.88%) |
| NA | 1 (0.06%) |
| Recipient CMV serostatus | |
| Positive | 765 (46.62%) |
| Negative | 745 (45.4%) |
| NA | 131 (7.98%) |
| Year of Transplant Categories (Year) | |
| < 2008 | 264 (16.09%) |
| 2008-2012 | 339 (20.66%) |
| 2013-2017 | 640 (39%) |
| 2018-2020 | 398 (24.25%) |
| Year of Translplant (Year) | |
| 2007 | 27 (1.65%) |
| 1991 | 2 (0.12%) |
| 1996 | 9 (0.55%) |
| 1998 | 21 (1.28%) |
| 1997 | 16 (0.98%) |
| 1993 | 4 (0.24%) |
| 1999 | 7 (0.43%) |
| 2001 | 18 (1.1%) |
| 2002 | 22 (1.34%) |
| 2005 | 38 (2.32%) |
| 2000 | 17 (1.04%) |
| 2004 | 17 (1.04%) |
| 2006 | 32 (1.95%) |
| 1994 | 5 (0.3%) |
| 2003 | 23 (1.4%) |
| 1995 | 5 (0.3%) |
| 2008 | 42 (2.56%) |
| 2009 | 65 (3.96%) |
| 1992 | 1 (0.06%) |
| 2013 | 95 (5.79%) |
| 2012 | 94 (5.73%) |
| 2011 | 83 (5.06%) |
| 2014 | 139 (8.47%) |
| 2010 | 55 (3.35%) |
| 2016 | 141 (8.59%) |
| 2015 | 127 (7.74%) |
| 2017 | 138 (8.41%) |
| 2018 | 169 (10.3%) |
| 2019 | 148 (9.02%) |
| 2020 | 81 (4.94%) |